Metabolism and pharmacokinetics of the anti-tumour agent 2,3,5-trimethyl-6-(3-pyridylmethyl) 1,4-benzoquinone (CV-6504)
1996

Study of CV-6504 as an Anti-Tumor Agent

Sample size: 20 publication 10 minutes Evidence: moderate

Author Information

Author(s): H J Hussey, M J Tisdale

Primary Institution: Pharmaceutical Sciences Institute, Aston University

Hypothesis

Does CV-6504 effectively inhibit the growth of murine adenocarcinomas?

Conclusion

CV-6504 shows significant anti-tumor activity in murine models, with effective concentrations found in tumors.

Supporting Evidence

  • CV-6504 was found to accumulate in tumors at effective concentrations.
  • Free CV-6504 inhibited tumor growth with an IC50 value of 3 µM.
  • Metabolites of CV-6504 were ineffective in vitro but showed similar anti-tumor effects in vivo.
  • Both MAC16 and MAC13 tumors had similar enzyme activity for metabolizing CV-6504.

Takeaway

CV-6504 is a medicine that helps stop tumors from growing in mice, and it works better than some other treatments.

Methodology

Mice were treated with CV-6504 and its metabolites, and tumor growth was measured over time.

Potential Biases

Potential bias due to the funding from Takeda Chemical Industries.

Limitations

The study was conducted only in mice, which may not fully represent human responses.

Participant Demographics

Male NMRI mice, weighing 20-25 g.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication